Superior in vivo sepsis models.
Every year, around 11 million people die of sepsis. In other words, 1 in every 5 deaths per year is due to sepsis. Vulgarized as “the body’s extreme response to an infection”, it can rapidly lead to tissue damage, progressing into organ failure and eventually death. In the USA only, sepsis costs the government $23 billion a year.
Although sepsis was first discovered in the 1800s by none other than Louis Pasteur (who showed the presence of bacteria in the blood of a patient suffering from puerperal septicemia), and despite all the advances in organ support techniques and anti-infective treatments, the mortality rate of sepsis today is still as high as 30-70%. With sepsis becoming an increasingly heavy burden on the healthcare system, PharmaLegacy has put forward multiple sepsis models to accelerate the search for better treatments. Keep browsing for more information on our LPS-induced and CLP-induced sepsis in mice models.
MODELS / SERVICES
Committed to quality:
- Rigorous adherence to international GLP and QA best practices
- Capacity to run 200+ concurrent animal studies
- 24/7 access to PharmaLegacy representatives
- 380,000 square feet of facility space
Over half of the top 20 pharmaceutical companies can’t be wrong. Choose PharmaLegacy.
Can you trust your animal model to provide you with the correct answers?
No animal study can predict with complete certainty how a therapy will perform in human subjects, but it is PharmaLegacy’s job to ensure that you come as close to certainty as possible. Download our brochure on non-human primate (NHP) models and see how PharmaLegacy ensures that y our studies utilize the most physiologically relevant models.